RxDoctor Payments Data

Daniel Sirica, MD

Neurology · Rochester, NYNPI 1609239060

Payments from drug & device makers

$16,532in general payments, 2019–2025

Across 42 payments — averaging $393.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Teva Pharmaceuticals USA, Inc.$359
  • Boston Scientific$276
  • Abbott$220
  • AbbVie$144
  • Neurocrine Biosciences, Inc.$139
  • plus $284 from 9 others

What the payments were for

  • Grants$15,00091%
  • Food & beverage$1,2307%
  • Education$3022%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,532 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$261,346
Medicare patients
159
Services billed
10,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine23$168,319
IngrezzaValbenazine Tosylate18$162,492
RytaryCarbidopa/Levodopa26$43,666
Carbidopa-LevodopaCarbidopa/Levodopa420$22,466
NeuproRotigotine13$14,344
Rivastigmine34$8,877
Carbidopa-Levodopa ErCarbidopa/Levodopa151$6,270
AmantadineAmantadine Hcl90$3,487
Entacapone27$3,097
Rasagiline Mesylate19$2,576
Primidone66$2,259
Propranolol Hcl ErPropranolol Hcl43$1,789
Levetiracetam36$1,644
Baclofen27$1,625
Gabapentin48$1,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$359$168,31923 claims
Neurocrine Biosciences, Inc.Ingrezza$139$162,49218 claims
UCB, Inc.Neupro$28$14,34413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →